OA10500A - Valaciclovir tablets containing colloidal silicon dioxide - Google Patents
Valaciclovir tablets containing colloidal silicon dioxide Download PDFInfo
- Publication number
- OA10500A OA10500A OA70052A OA70052A OA10500A OA 10500 A OA10500 A OA 10500A OA 70052 A OA70052 A OA 70052A OA 70052 A OA70052 A OA 70052A OA 10500 A OA10500 A OA 10500A
- Authority
- OA
- OAPI
- Prior art keywords
- tablet
- valaciclovir
- présent
- filler
- lubricant
- Prior art date
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 55
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title claims abstract description 36
- 229940093257 valacyclovir Drugs 0.000 title claims abstract description 36
- 229940075614 colloidal silicon dioxide Drugs 0.000 title claims abstract description 13
- 239000008187 granular material Substances 0.000 claims abstract description 32
- 239000000945 filler Substances 0.000 claims description 33
- 239000000314 lubricant Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 21
- 239000011230 binding agent Substances 0.000 claims description 20
- 239000000377 silicon dioxide Substances 0.000 claims description 20
- 229960001866 silicon dioxide Drugs 0.000 claims description 19
- 235000012239 silicon dioxide Nutrition 0.000 claims description 19
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 229940069328 povidone Drugs 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052710 silicon Inorganic materials 0.000 claims description 6
- 239000010703 silicon Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 3
- 229920003082 Povidone K 90 Polymers 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 5
- 206010019972 Herpes viral infections Diseases 0.000 claims 1
- 238000005461 lubrication Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229960004150 aciclovir Drugs 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 239000011928 denatured alcohol Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- -1 L-valine ester Chemical class 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RSZHAWGPXQABCU-UHFFFAOYSA-N O1C=COC=C1.[Si] Chemical compound O1C=COC=C1.[Si] RSZHAWGPXQABCU-UHFFFAOYSA-N 0.000 description 1
- 241000505673 Scintilla Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501127.6A GB9501127D0 (en) | 1995-01-20 | 1995-01-20 | Tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10500A true OA10500A (en) | 2002-04-10 |
Family
ID=10768317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA70052A OA10500A (en) | 1995-01-20 | 1997-07-16 | Valaciclovir tablets containing colloidal silicon dioxide |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US5879706A (fa) |
| EP (1) | EP0806943B1 (fa) |
| JP (1) | JP3350055B2 (fa) |
| KR (1) | KR100412298B1 (fa) |
| CN (2) | CN1313081C (fa) |
| AP (1) | AP666A (fa) |
| AT (1) | ATE190483T1 (fa) |
| AU (1) | AU710823B2 (fa) |
| BG (1) | BG63187B1 (fa) |
| BR (1) | BR9606769A (fa) |
| CA (1) | CA2210891C (fa) |
| CY (1) | CY2182B1 (fa) |
| CZ (1) | CZ296514B6 (fa) |
| DE (1) | DE69607146T2 (fa) |
| DK (1) | DK0806943T3 (fa) |
| EA (1) | EA000276B1 (fa) |
| EE (1) | EE03336B1 (fa) |
| ES (1) | ES2145425T3 (fa) |
| FI (1) | FI119722B (fa) |
| GB (1) | GB9501127D0 (fa) |
| GE (1) | GEP20022752B (fa) |
| GR (1) | GR3033677T3 (fa) |
| HU (1) | HU226131B1 (fa) |
| IL (1) | IL116830A (fa) |
| IN (1) | IN181318B (fa) |
| MY (1) | MY126346A (fa) |
| NO (1) | NO311488B1 (fa) |
| NZ (1) | NZ298846A (fa) |
| OA (1) | OA10500A (fa) |
| PL (1) | PL185307B1 (fa) |
| PT (1) | PT806943E (fa) |
| RO (1) | RO118175B1 (fa) |
| SK (1) | SK282030B6 (fa) |
| TR (1) | TR199700657T1 (fa) |
| UA (1) | UA68325C2 (fa) |
| UY (2) | UY25774A1 (fa) |
| WO (1) | WO1996022082A1 (fa) |
| ZA (1) | ZA96448B (fa) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| JP4097698B2 (ja) * | 1996-01-19 | 2008-06-11 | グラクソ、グループ、リミテッド | 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用 |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| DK1140034T3 (da) * | 1998-12-18 | 2004-03-08 | Abbott Lab | Formulering af divalproex-natrium med kontrolleret frigivelse |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| AU2002236166B2 (en) * | 2001-05-01 | 2006-12-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| US20040197396A1 (en) * | 2001-11-05 | 2004-10-07 | Fain Helen S | Anhydrous crystal form of valaciclovir hydrochloride |
| PL371732A1 (en) * | 2001-11-14 | 2005-06-27 | Teva Pharmaceutical Industries Ltd. | Synthesis and purification of valacyclovir |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20060147519A1 (en) * | 2002-06-24 | 2006-07-06 | Ashish Gogia | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| AU2003277433A1 (en) * | 2002-10-16 | 2004-05-04 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| EP1633753A1 (en) * | 2003-05-30 | 2006-03-15 | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| WO2005000850A2 (en) * | 2003-06-02 | 2005-01-06 | Teva Pharmaceutical Industries, Ltd. | Novel crystalline forms of valacyclovir hydrochloride |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| DK2821067T3 (en) | 2003-09-12 | 2017-12-04 | Amgen Inc | Quick solution formulation of cinacalcet |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| DE60301277T2 (de) * | 2003-12-09 | 2006-03-30 | Helm Ag | Pharmazeutische zubereitung enthaltend valaciclovir |
| US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
| KR101116747B1 (ko) | 2004-12-06 | 2012-02-22 | 에스케이케미칼주식회사 | 안정성이 개선된 말레인산 암로디핀 약제 조성물 |
| BRPI0608840B8 (pt) | 2005-03-07 | 2021-05-25 | Batyer Healthcare Ag | composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação |
| WO2006127217A2 (en) * | 2005-05-25 | 2006-11-30 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| WO2007090595A1 (en) * | 2006-02-06 | 2007-08-16 | Fidia Pharmaceutici S.P.A. | Solid formulations of valacyclovir hydrochloride |
| EP2023899A1 (en) * | 2006-05-10 | 2009-02-18 | Evonik Degussa GmbH | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
| KR20090018843A (ko) * | 2006-05-31 | 2009-02-23 | 버텍스 파마슈티칼스 인코포레이티드 | 인터류킨-1 베타 전환효소 억제제의 경구용 조절 방출 제제 |
| EP2040684B1 (en) * | 2006-07-11 | 2013-01-23 | LEK Pharmaceuticals d.d. | Multiple unit tablets |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| ITRM20080027A1 (it) * | 2008-01-18 | 2009-07-19 | Maria Balestrieri | Uso di aciclovir per il trattamento delle condilomatosi. |
| US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
| JP5583659B2 (ja) * | 2009-03-13 | 2014-09-03 | 富山化学工業株式会社 | ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミド含有錠剤および造粒末 |
| CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
| GB2515486A (en) * | 2013-06-24 | 2014-12-31 | Kraft Foods R & D Inc | Soluble Beverage Ingredients |
| KR101497508B1 (ko) * | 2013-12-20 | 2015-03-03 | 한국유나이티드제약 주식회사 | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2020049536A1 (en) * | 2018-09-07 | 2020-03-12 | Jubilant Generics Limited | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof |
| CN110279667B (zh) * | 2019-07-30 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
| CN115666516A (zh) * | 2020-06-01 | 2023-01-31 | 希尔帕医疗保健有限公司 | 包括卡培他滨的快速分散药物组合物 |
| TWI884340B (zh) * | 2020-12-01 | 2025-05-21 | 南韓商Ｌｇ化學股份有限公司 | 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 |
| WO2024047094A1 (en) * | 2022-08-31 | 2024-03-07 | Astrazeneca Ab | Pharmaceutical formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| DE68903605T2 (de) * | 1988-05-04 | 1993-04-01 | Smith Kline French Lab | Kautablette. |
| CH685978A5 (fr) * | 1991-01-30 | 1995-11-30 | Wellcome Found | Comprimes dispersables dans l'eau. |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9317146D0 (en) * | 1993-08-18 | 1993-10-06 | Wellcome Found | Therapeutic combinations |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
-
1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
-
1996
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
-
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
-
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
-
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA10500A (en) | Valaciclovir tablets containing colloidal silicon dioxide | |
| AP662A (en) | Anhydrous crystalline valaciclovir hydrochloride. | |
| AU722304B2 (en) | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application | |
| HK1002851B (en) | Valaciclovir tablets containing colloidal silicon dioxide | |
| MXPA97005459A (en) | Valaciclovir tablets containing silicon dioxide color | |
| HK1003055B (en) | Guanine derivative | |
| HK1003055A1 (en) | Guanine derivative | |
| MXPA97005462A (en) | Derived from guan |